NDA 206334 · Melinta Therap
Orbactiv
Oritavancin Diphosphate · Intravenous · Lipoglycopeptide Antibacterial
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Aug 6, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
2 Phase 3, 0 recruiting
FAERS reports
920
352 serious, 32 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 15, 2026.
ORBACTIV is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Acute Bacterial Skin and Skin Structure Infections ORBACTIV ® (oritavancin) is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus dysgalactiae , Streptococcus anginosus group (includes S. anginosus , S. intermedius , and S. constellatus ), and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Oritavancin is an antibacterial drug [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 6, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewSummary ReviewLabel
1 products under this application
- ORBACTIV · ORITAVANCIN DIPHOSPHATE EQ 400MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Oritavancin Diphosphate" as an intervention, any sponsor and status, largest first.
- Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionPivotal-lookingCompleted
Melinta Therapeutics, Inc.Industry
NCT01252732 · 1,019 participants · Start Dec 2010 · Primary completion Jun 2013
Drug: Single-Dose IV Oritavancin Diphosphate; IV Vancomycin · For: Wound Infection; Abscess; Systemic Inflammation and 1 more
Sites: La Mesa, California
- Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)Pivotal-lookingCompleted
Melinta Therapeutics, Inc.Industry
NCT01252719 · 968 participants · Start Dec 2010 · Primary completion Oct 2012
Drug: Single-Dose IV Oritavancin Diphosphate; IV Vancomycin and 1 more · For: Wound Infection; Abscess; Systemic Inflammation and 1 more
Sites: Chula Vista, California
- A Study to Assess the Cardiac Safety of Oritavancin in Healthy ParticipantsPivotal-lookingCompleted
Melinta Therapeutics, Inc.Industry
NCT01762839 · 150 participants · Start Dec 27, 2012 · Primary completion Jan 2013
Drug: Single-Dose IV Oritavancin Diphosphate; Placebo and 1 more · For: Healthy
Sites: West Bend, Wisconsin
- Relative Exposure and Safety Study of Kimyrsa in ABSSSI PatientsPivotal-lookingCompleted
Melinta Therapeutics, Inc.Industry
NCT03873987 · 102 participants · Start Jul 16, 2019 · Primary completion Aug 27, 2019
Drug: Current Formulation of Oritavancin; Kimyrsa · For: Acute Bacterial Skin and Skin Structure Infection
Sites: Chula Vista, California; La Mesa, California; Burr Ridge, Illinois · 4 sites in all
Melinta Therapeutics, LLCIndustry
NCT02134301 · 41 participants · Start May 2014 · Primary completion Nov 4, 2025
Drug: Oritavancin · For: Gram-positive Bacterial Infections
Sites: Little Rock, Arkansas; Orange, California; San Diego, California · 8 sites in all
Melinta Therapeutics, Inc.Industry
NCT02340988 · 36 participants · Start Apr 2015 · Primary completion Sep 2015
Drug: Single-Dose IV Oritavancin Diphosphate and Warfarin; Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose · For: Healthy
Sites: West Bend, Wisconsin
Melinta Therapeutics, Inc.Industry
NCT01784536 · 16 participants · Start Jan 2013 · Primary completion Mar 2013
Drug: Single-Dose IV Oritavancin Diphosphate · For: Healthy
Sites: West Bend, Wisconsin
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use175
- pruritus165
- urticaria105
- chills90
- rash86
- back pain83
- dyspnoea81
- nausea68
- infusion related reaction62
- erythema58
- chest pain56
- drug ineffective49
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 47 |
| 2016 | 159 |
| 2017 | 182 |
| 2018 | 141 |
| 2019 | 82 |
| 2020 | 73 |
| 2021 | 41 |
| 2022 | 67 |
| 2023 | 38 |
| 2024 | 36 |
| 2025 | 30 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orbactiv (Oritavancin Diphosphate)
2024 spending
$280K
Beneficiaries
46
83 claims
Per beneficiary
$6,092
$34.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $719,116 |
| 2021 | $1,008,342 |
| 2022 | $642,766 |
| 2023 | $230,797 |
| 2024 | $280,232 |
Part B: Orbactiv (Oritavancin Diphosphate) · HCPCS J2407
2024 spending
$2.0M
Beneficiaries
336
609 claims
Per beneficiary
$5,937
2024 ASP limit $27.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,087,076 |
| 2021 | $4,386,715 |
| 2022 | $3,553,178 |
| 2023 | $1,767,869 |
| 2024 | $1,994,666 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Melinta Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.